SALIVARY ANALYSIS FOR DETERMINATION OF DEXTROMETHORPHAN METABOLIC PHENOTYPE

被引:66
作者
HOU, ZY
PICKLE, LW
MEYER, PS
WOOSLEY, RL
机构
[1] GEORGETOWN UNIV,SCH MED,DEPT PHARMACOL,3900 RESERVOIR RD NW,WASHINGTON,DC 20007
[2] GEORGETOWN UNIV,SCH MED,DIV CLIN PHARMACOL,WASHINGTON,DC 20007
[3] GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007
[4] GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007
关键词
D O I
10.1038/clpt.1991.48
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Debrisoquin oxidative phenotype is a determinant of pharmacologic response for many drugs. Poor and extensive metabolizers can be identified by the dextromethorphan metabolic ratio (dextromethorphan/dextrorphan). We developed and tested a method to determine debrisoquin phenotype on the basis of the metabolic ratio in saliva. Each of 62 normal volunteers was given a 50 mg capsule of dextromethorphan hydrobromide and collected urine (0 to 8 hours) and saliva (at 3 hours). Dextromethorphan and dextrorphan in saliva and urine were assayed by HPLC. The distributions of paired urinary and 3-hour salivary metabolic ratios of samples from 61 subjects were compared. The urinary and salivary metabolic ratios were distributed trimodally and bimodally, respectively. The Spearman rank correlation coefficient for logarithm of urinary metabolic ratio vs that of salivary metabolic ratio was 0.704. All the poor metabolizers identified by urinary metabolic ratio were also identified by the metabolic ratio in saliva at 3 hours (100% concordance). This study demonstrates that salivary analysis for determination of dextromethorphan metabolic phenotype is feasible.
引用
收藏
页码:410 / 419
页数:10
相关论文
共 26 条
[1]   THE DISTRIBUTION OF DEBRISOQUINE METABOLIC PHENOTYPES AND IMPLICATIONS FOR THE SUGGESTED ASSOCIATION WITH LUNG-CANCER RISK [J].
CAPORASO, N ;
PICKLE, LW ;
BALE, S ;
AYESH, R ;
HETZEL, M ;
IDLE, J .
GENETIC EPIDEMIOLOGY, 1989, 6 (04) :517-524
[2]  
CONNEY AH, 1982, CANCER RES, V42, P4875
[3]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[4]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187
[5]  
FACCINI GB, 1990, CLIN CHEM, V36, P387
[6]   CHARACTERIZATION OF THE COMMON GENETIC-DEFECT IN HUMANS DEFICIENT IN DEBRISOQUINE METABOLISM [J].
GONZALEZ, FJ ;
SKODA, RC ;
KIMURA, S ;
UMENO, M ;
ZANGER, UM ;
NEBERT, DW ;
GELBOIN, HV ;
HARDWICK, JP ;
MEYER, UA .
NATURE, 1988, 331 (6155) :442-446
[7]   ASSESSMENT OF THE DEBRISOQUIN AND DEXTROMETHORPHAN PHENOTYPING TESTS BY GAUSSIAN MIXTURE DISTRIBUTIONS ANALYSIS [J].
HENTHORN, TK ;
BENITEZ, J ;
AVRAM, MJ ;
MARTINEZ, C ;
LLERENA, A ;
COBALEDA, J ;
KREJCIE, TC ;
GIBBONS, RD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) :328-333
[8]   METOPROLOL AND MEPHENYTOIN OXIDATION POLYMORPHISMS IN FAR EASTERN ORIENTAL SUBJECTS - JAPANESE VERSUS MAINLAND CHINESE [J].
HORAI, Y ;
NAKANO, M ;
ISHIZAKI, T ;
ISHIKAWA, K ;
ZHOU, HH ;
ZHOU, BJ ;
LIAO, CL ;
ZHANG, LM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (02) :198-207
[9]  
HOU ZY, 1989, CLIN PHARMACOL THER, V47, P159
[10]   EFFECT OF LIVER-DISEASE ON DEXTROMETHORPHAN OXIDATION CAPACITY AND PHENOTYPE - A STUDY IN 107 PATIENTS [J].
LARREY, D ;
BABANY, G ;
TINEL, M ;
FRENEAUX, E ;
AMOUYAL, G ;
HABERSETZER, F ;
LETTERON, P ;
PESSAYRE, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) :297-304